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ABSTRACT 
Objective: The objective of the study was to develop a new, simple, accurate, precise and reproducible RP-UPLC method for the estimation of 
bumetanide in bulk and pharmaceutical dosage form.  
Methods: Acquity SB C18, 2 x 100 mm, 1.8 µmm, 5µ particle size column with the mobile phase consisting of water: acetonitrile in the ratio of 30:70 
v/v were used. The effluents were moniRTat 254 nm and the flow rate was 1.0 ml/minute.  
Results: The retention time was 0.852 min. Quantitative linearity was obeyed in the concentration range of 12.5 to 75 μg/ml. The correlation coefficient 
for bumetanide was found to be 0.999. Recovery and assay studies of bumetanide were within 99 to 102%, indicating that the proposed method can be 
adaptable for quality control analysis of bumetanide. The % RSD for precision and accuracy of the method was found to be less than 2%. Bumetanide 
was subjected to stress environment of degradation in aqueous solutions including oxidation, hydrolysis, thermal and photolysis degradation.  
Conclusion: Proposed method was found to be simple, accurate, precise, and quick and can be used for regular analysis. This condition was applied 
to tablet dosage form. The statistical parameters and recovery studies were reported. 
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The best way to illustrate the quality of a drug substance is to verify 
its purity. The basic task of pharmaceutical studies includes how to 
assure the quality safety and efficacy of drugs [1]. The quality of the 
drugs encompasses the potency, uniformity, purity, pharmacological 
action, stability etc. Therefore, it becomes essential for the 
manufacturer to maintain the quality and produce effective safe and 
non-toxic forms of drugs by developing newer analytical methods. 
The methods of identification, estimation of drug substances and 
drug products are divided into physical, chemical, physicochemical 
and biological. Physical methods of analysis involve the use of 
physical reactions between the analyte and reagent. 
Physicochemical methods are used to study the physical phenomena 
that take place as a result of chemical reactions [2]. The techniques 
are usually based on the study of optical (emission, e. g., 
fluorimetry), absorption (UV, visible, IR spectrophotometry), 
electrochemical (potentiometry, amperometry, polarography) 
characteristics and chromatographic mode (HPLC, GLC, HPTLC) 
which include separation and quantification (e. g. photodiode array 
detector). The chromatography is very popular technique and it is 
frequently used analytically. There are various types of 
chromatographic techniques namely paper chromatography, gas 
chromatography, liquid chromatography, thin layer chromatography 
(TLC), ion exchange chromatography, high-performance liquid 
chromatography (HPLC) and ultra-performance liquid chroma-
tography (UPLC) [3]. High-performance liquid chromate-graphy 
which is also called as high-pressure liquid chromatography. It is a 
popular analytical technique used for the separation, identification, 
and quantification of each constituent of the mixture. HPLC is a 
highly developed technique for column liquid chromatography. The 
solvent generally flows through a column with the assist of gravity 
but in HPLC technique the solvent is forced under high pressures up 
to 400 atmospheres. Hence that sample can be separated into 
different constituents with the assist of difference in relative 
affinities. In HPLC, pumps are used to pass pressurized liquid 
solvent. It also includes the sample mixture which is permitted to 
enter into a column filled with solid adsorbent material. The 
interaction of every sample component varies which causes a 
difference in flow rates of each component and finally leads to 
separation of components in column [4]. UPLC is a modern 
technique which gives a new approach for liquid chromatography. 
UPLC develops primarily in three areas: speed, resolution, and 
sensitivity [5]. UPLC shows an extraordinary development in speed, 
resolution as well as the sensitivity of analysis by using particle size 
less than 2 µm and the system is operational at higher pressure. The 
mobile phase can be able to run at better linear velocities as 
compared to HPLC [6]. This practice is considered as a new central 
point in the field of liquid chromatographic studies [7]. 
Bumetanide is a loop diuretic used to treat heart failure. The world anti-
doping agency (WADA) and national football league (NFL) consider the 
supplement a banned ingredient for athletes. Its alleged use is to disguise 
steroids by increasing urine output. Bumetanide [3-(Aminosulfonyl)-5-
(butylamino)-4-phenoxy-benzoic] acid is a potent high-ceiling or loop 
diuretic that has an efficiency 40 to 60 times greater than furosemide [8]. 
The chemical formula and molecular weight of bumetanide are 
C17H20N2O5S and 364.416 respectively. This compound belongs to the 
sulfonamide family, although its structure differs considerably from 
furosemide and others of its class. The main aim and objective of this 
work was method development, validation and degradation studies of 
bumetadnide in pharmaceutical dosage form by RP-UPLC.  
MATERIALS AND METHODS 
Instrumentation 
UPLC instrument used was of WATERS UPLC 2965 SYSTEM with 
auto-injector and PDA detector. Software used was Empower 2. UV-
VIS spectrophotometer PG Instruments T60 with special 
bandwidths of 2 mm and 10 mm and matched quartz was used for 
measuring absorbance for bumetanide solutions. 
Chemicals 
HPLC grade acetonitrile, orthophosphoric acid, and all other 
chemicals were purchased from Rankem chemical division, 
Hyderabad. HPLC grade water was used throughout the study.  
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Preparation of orthophosphoric acid (0.1%) 
0.1 gms of orthophosphoric acid was accurately weighed and transferred 
to a 1000 ml volumetric flask. Then 1000 ml of water was added to the 
volumetric flask and degassed for removal of water bubbles. 
Preparation of mobile phase 
Buffer solution and HPLC grade acetonitrile were transferred to the 
volumetric flask in the ratio of 30:70. Prior to use, the mobile phase 
was degassed in an ultrasonic water bath for 5 min and the solution 
was filtered through 4.5µ filter paper under vacuum filtration. 
Standard solution preparation  
Bumetanide (5 mg) was accurately weighed and transferred into a 
10 ml clean dry volumetric flask and 7 ml of diluents was added. The 
solution was sonicated for 30 min and made up to the final volume 
with diluents. From the above solution, 1 ml was transferred to 10 
ml volumetric flask and then made up to final volume with diluents.  
Sample preparation 
Twenty tablets were weighed and calculated the average weight of 
each tablet. Then the weight equivalent to 1 tablet was transferred 
to a 100 ml volumetric flask. Diluents (80 ml) were added and 
sonicated for 25 min. Then the volume was made up of diluents and 
filtered. From the filtered solution, 1 ml was transferred to 10 ml 
volumetric flask and made up to final volume with diluent. 
Method development 
Initially, reverse phase liquid chromatography separation was tried 
to develop using various ratios of water: methanol and acetonitrile 
as mobile phases, in which the drug did not respond properly and 
the resolution was also poor. The organic content of mobile phase 
was also investigated to optimize the separation of the drug. 
Thereafter, orthophosphoric acid: acetonitrile were taken in 30:70% 
v/v at a flow rate of 0.4 ml/min. Acquity SB C18, 2 x 100 mm, 1.8 
µmm, 5µ particle size column was used as the stationary phase. It 
was selected to improve resolution and the tailing of both peaks 
which were reduced considerably and brought close to 1.5. 
Detection was tried at various wavelengths from 210 nm to 280 nm 
for drug analysis. The wavelength at which bumetanide showed 
maximum absorption at 254 nm was selected as the detection 
wavelength for PDA detector. The retention times were found to 
about 0.852 min. The obtained chromatogram was shown in fig. 5. 
Method validation 
System suitability 
Sample solution and six replicate injections were injected from freshly 
prepared standard solutions. Each solute was analyzed for their peak 
area, theoretical plates (N), resolution (R) and tailing factors [9]. 
Linearity 
Five solutions ranging from 12.5-75 μg/ml were prepared. Each 
experiment was performed in triplicate according to the optimized 
chromatographic situation. The peak area of the chromatograms 
was plotted against the concentration of bumetanide to obtain the 
calibration curve [10]. 
Precision 
Precision was determined as repeatability and intermediate 
precision by analyzing the samples in accordance with ICH 
guidelines. Determinations were performed on the same day as well 
as well as on consequent days [11]. Each stage of precision was 
investigated by 3 sequential replicates of injections of 
concentrations of 50, 100 and 200 µg/ml. The precision was 
expressed as the relative standard deviation (RSD).  
Repeatability 
Bumetanide sample solutions of 10μg/ml concentration were spiked 
for repeatability of the method. The precision was examined by 
analyzing six replicates. The retention time and percentage relative 
standard deviation were calculated.  
Intermediate precision  
The intermediate precision was studied on the next day of sample 
preparation. Working standard solution (50 ppm) of bumetanide at 
three concentration levels (50 %, 100 %, and 150 %) was analyzed. 
The % RSD of the analytical responses was calculated. 
Accuracy 
The study of recovery of bumetanide was evaluated in triplicate at three 
concentration levels, i.e. 50%, 100% and 150% of working concentration 
of the sample [12]. The percentage of recoveries were calculated. 
LOD and LOQ 
A series of solutions were injected and the signal-to-noise ratio for 
each compound was calculated. This process was continued until the 
S/N ratio was 3 for LOD and 10 for LOQ. 
Robustness 
Robustness was carried by varying three parameters from the 
optimized chromatographic conditions such as flow rate (±0.1 
ml/min), mobile phase composition (±5%) and column temperature 
(±5 °C) [13].  
Degradation studies 
Oxidation 
The stock solution of bumetanide (1 ml) was mixed with 1 ml of 
20% hydrogen peroxide (H2O2). The solutions were kept for 30 min 
at 60 °c. For UPLC study, the resultant solution was diluted to obtain 
50µg/ml solution and 1.0 µl was injected into the system. The 
chromatograms were recorded to assess the stability of the sample. 
Acid degradation studies 
The Stock solution of bumetanide (1 ml) was mixed with 1 ml of 2N 
hydrochloric acid and refluxed for 30 min at 60 °C. The resultant 
solution was diluted to obtain 50µg/ml solution and injected into 
the system. The chromatograms were recorded to assess the 
stability of the sample.  
Alkali degradation studies 
The stock solution bumetanide (1 ml) was mixed with 1 ml of 2N 
sodium hydroxide and refluxed for 30 min at 60 °C. The resultant 
solution was diluted to obtain 50µg/ml solution and injected into 
the system. The chromatograms were recorded to assess the 
stability of the sample. 
Dry heat degradation studies 
The standard drug solution was placed in an oven at 105 °C for 6 h 
for dry heat degradation studies. For UPLC study, the resultant 
solution was diluted to 50µg/ml solution and 1.0 µl was injected into 
the system and the chromatograms were recorded to assess the 
stability of the sample. 
Photostability studies 
500µg/ml solution was prepared and exposed to UV light by keeping the 
beaker in UV Chamber for 1day. For UPLC study, the resultant solution 
was diluted to 50µg/ml solutions and was injected into the system. The 
chromatograms were recorded to assess the stability of the sample.  
Neutral degradation studies 
Stress testing under neutral conditions was studied by refluxing the 
drug in water for 1 hour at a temperature of 60 °. For UPLC study, 
the resultant solution was diluted to 50µg/ml solution and injected 
into the system. The chromatograms were recorded to assess the 
stability of the sample. 
Assay 
Standard solution and sample solution were injected into the 
chromatographic system and the peak area response for the 
analytes was measured. Standard preparations are made from the 
API and sample preparations are prepared from the formulation. 
Both sample and standard preparations were analyzed in six 
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replicates. Standard was taken as the reference for the estimation of 
the drug in the formulation. 
RESULTS 
Chromatograms depicting the method development of 
bumetanide 
Different chromatographic conditions were experimented to achieve 
the better efficacy of the chromatographic system. Parameters such 
as mobile phase composition, the wavelength of detection, column, 
column temperature, pH of mobile phase and diluents were 
optimized. Several proportions of buffer and solvents were 
evaluated in order to obtain an appropriate composition of the 
mobile phase. Choice of retention time, tailing, theoretical plates and 
runtime were major tasks while developing the method. A perfect 
peak was eluted at 30:70 (buffer: solvent) in an isocratic mobile 
phase flow rate. All the trails and the typical chromatogram obtained 
for bumetanide are shown in fig. 1-5. 
 
 
Fig. 1: First trail run of bumetanide 
 
 
Fig. 2: Second trail run of bumetanide 
 
 
Fig. 3: Third trail run of bumetanide 
 
System suitability  
System suitability parameters such as retention factor (0.852), 
plate number (9177), tailing factor (1.5), RSD (1.0), standard 
deviation (907.8) and mean area (132667) were evaluated for 
six replicate injections of the drug.  
The results were given in table 1. 
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Fig. 4: Fourth trail run of bumetanide 
 
 
Fig. 5: Typical chromatogram of bumetanide by the proposed method 
 
Table 1: System suitability data of bumetanide 
Parameter Result 
RT 0.852 min/ml 
Area(mean) 132667 
USP plate count 9177 
USP tailing 1.5 
*Standard deviation 907.8 
%RSD 1.0 
*Number of experiments: 6, % RSD: Relative standard deviation 
 
 
Fig. 6: Linearity plot of bumetanide 
 
Table 2: linearity concentration and response 
Linearity level (%) Concentration (ppm) Area 
0 0 0 
25 12.5 34131 
50 25 66387 
75 37.5 96431 
100 50 130931 
125 62.5 159408 
150 75 187732 
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Linearity 
A linear correlation was obtained between the peak area used and 
the absorbance Vs concentrations of bumetanide. The calibration 
curve was linear for concentrations between 12.5 and 75µg/ml.  
The linearity of the calibration curves was validated by the values of 
the regression correlation coefficients (r2). The correlation 
coefficient was found to be 0.999. The results of the linearity 
experiment were listed in table 2 and plot was presented in fig. 6. 
Precision 
The % RSD for the repeatability and intraday precision was 
reported to be 0.1 and 0.7. The results of precision were shown in 
table 3 and 4. 
  
Table 3: Repeatability data 








Standard deviation 1370.7 
%RSD 1.0 
*Number of experiments-6, %RSD: Relative standard deviation 
 
Table 4: Intermediate precision 








Standard deviation 904.8 
%RSD 0.7 
*Number of experiments-6, % RSD: Relative standard deviation 
 
Accuracy  
The mean % recovery at concentrations ranging from (spike level) 
50%, 100%, 150% was found to be 98.02 to 100.32 which were in 
the acceptance limit of 98.0 to 102.0 %. The RSD was not more than 
2.0%. The results were shown in table 5. 
Robustness 
The robustness method was evaluated by deliberately varying the 
chromatographic conditions. The % RSD of flow minus, flow plus, 
mobile phase minus, mobile phase plus, temperature minus and 
temperature plus were found to be 0.6, 1.6, 0.8, 0.7, 1.0, 0.4 
respectively. The parameters like tailing factor and retention time 
showed adherence to the limits. The data obtained with these 
changes were mentioned in table 6. 
LOD and LOQ  
Ratios of 3:1 and 10:1 signal-to-noise were considered as acceptable 
criteria for estimation of the LOD and LOQ, respectively. So, the limit 
of detection and the limit of quantification were determined to be 
0.84 and 0.27 µg/ml, respectively. Chromatograms showing LOD and 
LOQ were as shown in fig. 7 and 8. 
Forced degradation studies  
Degradation studies were performed with the formulation and 
degraded samples were injected.  
The % degradation of the drug for acid, alkali, oxidation, 
thermal, UV and water were 4.54, 2.92, 1.81, 0.86, 0.89, 0.52, 
respectively. Data was recorded in table 7. 
 
Table 5: Recovery of assay method 
 Level Amount spiked (μg/ml) % recovery *Mean % recovery 
50% 25 99.40 99.29% 
25 98.02 
25 99.71 
100% 50 99.51 
50 99.14 
50 98.96 
150% 75 99.58 
75 99.00 
75 100.32 
*Number of experiments: 3, % RSD: Relative standard deviation 
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Table 6: Robustness data of bumetanide 
Parameter  %RSD* 
Flow Minus 0.6 
Flow Plus 1.6 
Mobile phase Minus 0.8 
Mobile phase Plus 0.7 
Temperature minus 1.0 
Temperature plus 0.4 
Number of experiments: 3, %RSD: Relative standard deviation 
 
 
Fig. 7: LOD chromatogram of bumetanide 
 
 
Fig. 8: LOQ chromatogram of bumetanide 
 
Table 7: Forced degradation studies of bumetanide 
S. No. Degradation condition % drug degraded 
1 Acid 4.54 
2 Alkali 2.92 
3 Oxidation 1.81 
4 Thermal 0.86 
5 UV 0.89 
6 Water 0.52 
 
Table 8: Assay of formulation of bumetanide 








Standard deviation 1.03 
%RSD 1.03 
*Number of experiments-6, % RSD: Relative standard deviation 
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Assay of marketed formulation 
Standard solution and sample solution were injected separately into 
the system. The % RSD of the marketed formulation was found to be 
1.03. The drug present in the sample was calculated and results 
were summarized in table 8. 
DISCUSSION 
Analytical method development helps to know the vital process 
parameters and to reduce their influence on accuracy and precision. 
Analytical methods must be used by following GMP and GLP guiding 
principles and must be developed using the protocols and 
acceptance criteria set out in the ICH guidelines Q2 (R1). Method 
validation helps to validate the analytical method for a diversity of 
concentrations so that the change in formulation or concentration 
does not need additional validation. Once the methods have been 
developed, qualified and validated the impact they have on out-of-
specification rates and process capability needs to be quantified. 
Methods are evaluated to determine its effectiveness for future use 
[14]. Several mobile phase compositions were tried to develop a 
new RP-UPLC method. A satisfactory separation with good peak 
symmetry was obtained with aquity SB C18, 2x100 mm, 1.8 µmm, 5µ 
column using mobile phase containing orthophosphoric acid: 
acetonitrile (30:70) (v/v) at a flow rate of 0.4 ml/min. Quantification 
was achieved at UV detection at 254 nm based on peak area. The 
retention time for bumetanide was found to be 0.852 min. The 
optimized method was validated as per ICH guidelines. 
System suitability tests were an integral part of a liquid 
chromatographic technique. They were used to verify that the 
proposed method was able to produce good resolution between the 
peaks of interest with high reproducibility. Retention factor, plate 
number (N), tailing factor (T), and RSD evaluated were within the 
range of acceptable limits [15]. The accuracy of an analytical 
procedure expresses the closeness of agreement between the value 
which is accepted either as a conventional true value or an accepted 
reference value and the value found [16]. The standard addition and 
recovery experiments were conducted to demonstrate the accuracy 
of the method. The values of % recovery were found to be 99.29%, 
indicates that the method was accurate. 
The precision of an analytical method gives information on the 
random error. It expresses the agreement between a series of 
measurements obtained from multiple sampling of the same 
homogeneous sample under prescribed conditions. Six injections at 
the unchanged concentration were analyzed on the same day and 
two different days for verifying the variation in the precision. The % 
RSD for bumetanide was within the acceptable limit of ≤2. Hence the 
method is reproducible on different days with different analyst and 
column. This indicates that the method was precise. The linearity of 
the method was tested in order to demonstrate the proportional 
relationship of response versus analyte concentration over the 
working range [17]. It is usual practice to perform linearity 
experiments over a wide range of analyte. This gives confidence that 
the response and concentration are proportional. It also accordingly 
ensures that calculation can be performed using a single reference 
standard/working standard, relatively than the equation of a 
calibration line. Bumetanide showed a linearity of response between 
12.5-75 μg/ml. These were represented by a linear regression 
equation as follows: y = 2509. x+2328. The regression line was 
established by least squares method. The correlation coefficient (R2) 
for bumetanide was found to be greater than 0.999. Hence the 
curves established were linear. 
The limit of detection (LOD) and limit of quantification (LOQ) were 
established based on the concentration of the analyte that would 
yield signal-to-noise ratios of 3 for LOD and 10 for LOQ respectively. 
LOD and LOQ were found to be 0.27µg/ml and 0.80µg/ml 
respectively. In all deliberately varied conditions, the SD of retention 
times of bumetanide was found to be well within the acceptable 
limit. The tailing factor for all the three peaks was found to be<1.5. 
Robustness was carried by changing three parameters from the 
optimized chromatographic conditions such as making small 
changes in flow rate (±0.1 ml/min), mobile phase composition 
(±5%) and column temperature (±5 °C). It was observed that the 
small changes in these operational parameters did not lead to 
changes of the retention time of the peak of interest and the %RSD 
was not more than 2.0. The degree of reproducibility of the results 
proves that the method was robust. Specificity was tested by 
injecting the sample by spiking with suitable levels of impurities and 
indicating the separation of these impurities separately and/or from 
other components in the sample matrix. There are no placebo and 
excipients peaks interference with standard and analytic peak. So it 
proves method was selective. 
CONCLUSION 
Chromatographic conditions used were stationary phase equity SB 
C18 2 x 100 mm, 1.8µ column and a mobile phase consisting of 0.1% 
orthophosphoric acid: Acetonitrile in the ratio of 30:70. The flow 
rate was maintained at 1 ml/min. The detection wavelength in UV 
was 254 nm. The column temperature was 30 °C. System suitability 
parameters were reported by injecting the standard six times and 
results were well under the range of acceptance criteria. Linearity 
study was carried out between 25 % to150 % levels were within 
acceptable range. Precision had shown good results which are 
acceptable to carry out a regular analysis. LOD and LOQ were found 
to be 0.27µg/ml and 0.80µg/ml, respectively. By using above 
method, assay of the marketed formulation was carried out. The 
mean percentage of recovery of the formulation was 99.60%. The 
Proposed method was found to be simple, accurate, precise, and 
quick and could be used for regular analysis. This condition was 
applied to tablet dosage form. The statistical parameters and 
recovery studies were reported. Degradation studies of bumetanide 
were done, in all conditions purity threshold was more than purity 
angle and within the acceptable range. 
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